{"doi":"10.1517/13543776.15.5.621","title":"Novel peptides targeting the hepatocyte growth factor receptor c-Met for the treatment of cancer","abstract":null,"journal":"Expert Opinion on Therapeutic Patents","year":2005,"id":682480,"datarank":0.20794415416798362,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"self_citation_contribution":0.20794415416798362,"citation_network_contribution":0.0,"self_endowment_contribution":0.20794415416798362,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1782995,"name":"Neil R Michaud","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Novel peptides targeting the hepatocyte growth factor receptor c-Met for the treatment of cancer","abstract":"Dysregulated growth factor signalling is an important hallmark of cancer. The receptor tyrosine kinase c-Met has been implicated in the development of many carcinomas and sarcomas, and multiple therapeutic approaches to target the hepatocyte growth factor (HGF)/c-Met signalling axis are being pursued by several companies. Here, monomeric peptides or chemically-conjugated multimeric polypeptides that antagonise binding of HGF to c-Met and abrogate c-Met function are claimed as a treatment for cancer.","is_dataset_classified":null,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"26207759","pmcid":null,"openalex_id":"https://openalex.org/W2046349844","authors":[],"funders":[],"total_grants":0,"fwci":0.1499,"citation_percentile":0.51390374,"influential_citations":0,"citation_trend":[{"year":2019,"count":1},{"year":2022,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://www.tandfonline.com/doi/pdf/10.1517/13543776.15.5.621","host_type":"publisher"},{"url":"https://doi.org/10.1517/13543776.15.5.621","host_type":"journal"}],"fields_of_study":["Liver physiology and pathology","PI3K/AKT/mTOR signaling in cancer","Pancreatic function and diabetes"],"mesh_terms":[],"keywords":["Hepatocyte growth factor","C-Met","Hepatocyte Growth Factor Receptor","Receptor tyrosine kinase","Cancer research","Tyrosine kinase","Cancer","Receptor","Growth factor","Cancer cell","Function (biology)","Kinase","Signal transduction","Chemistry","Cell biology","Biology","Biochemistry","Genetics"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-17T20:31:56.739124Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}